Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2018

Study Completion Date

February 16, 2021

Conditions
Prostate Cancer
Interventions
DRUG

Standard of care ADT + (HMB + arginine + glutamine)

"1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months"

OTHER

Standard of care ADT

Patient will receive standard of care androgen deprivation therapy (ADT) alone

Trial Locations (1)

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT01607879 - Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation | Biotech Hunter | Biotech Hunter